Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mersana Therapeutics, Inc. (MRSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.0000+0.0900 (+1.83%)
At close: 04:00PM EDT
5.0000 0.00 (0.00%)
After hours: 06:43PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.9100
Open5.0000
Bid4.8500 x 2200
Ask5.2300 x 1300
Day's Range4.8500 - 5.2450
52 Week Range2.6800 - 14.8000
Volume5,259,222
Avg. Volume1,490,380
Market Cap359.559M
Beta (5Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-2.1490
Earnings DateFeb 24, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
  • Zacks

    Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?

    Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • GlobeNewswire

    Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 104,475 s

  • GlobeNewswire

    Mersana Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at three upcoming investor conferences. Details are as follows: Cowen’s 3rd Annual Oncology Innovation SummitFormat: Fireside Chat Date/Time: Thursday, June 2, 2022, at

Advertisement
Advertisement